FDA Approval for Children
Valtoco (diazepam nasal spray) is FDA-approved for children aged 6 years and older to treat seizure clusters associated with epilepsy. It's indicated for acute treatment in patients who already take other antiseizure medications.[1]
Safety Data from Clinical Trials
In pivotal trials like ART-IST 1 and 2, children 6-11 years (n=46) showed similar safety profiles to adults, with common side effects including nasal discomfort (17%), headache (13%), and upper respiratory infection (11%). Serious adverse events were rare, and no new safety signals emerged in pediatric subgroups. The 10 mg dose is approved for kids weighing 10 kg or more.[1][2]
Age and Weight Restrictions
Not approved for children under 6 years or those under 10 kg due to limited data. Off-label use in younger kids lacks robust safety evidence and risks respiratory depression from benzodiazepines.[1]
Common Side Effects in Kids
- Nasal issues: burning, congestion, or runny nose (up to 20% in trials).
- Sleepiness or sedation (15-20%).
- Less frequent: agitation, ataxia, or respiratory issues, especially if overdosed or combined with opioids/CNS depressants.[1][3]
Risks and Warnings
Benzodiazepines like Valtoco carry black box warnings for respiratory depression, abuse potential, and withdrawal risks. In epilepsy kids, monitor for tolerance with repeated use. Avoid in acute narrow-angle glaucoma or severe respiratory issues. Long-term safety beyond acute cluster treatment is unestablished.[1]
How It Compares to Diastat
Valtoco offers faster absorption (peak in 1.3-1.4 hours) than rectal Diastat gel (approved for ages 2+), making it preferable for school or public settings. Seizure cessation rates were comparable (about 50% at 2 hours) in head-to-head data.[2][4]
When to Consult a Doctor
Safe under medical supervision for approved ages, but discuss individual risks like comorbidities or concurrent meds. Emergency use requires training on proper nasal administration.[1]
[1]: FDA Valtoco Label
[2]: NEJM ART-IST Trials
[3]: Epilepsy Foundation on Valtoco
[4]: Study on Diazepam Formulations